22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Merck has revealed positive data from the Phase III KEYNOTE-426 trial of Keytruda (pembrolizumab) plus Inlyta (axitinib) in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC). 19 October 2018
The US Food and Drug Administration’s Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of prucalopride (SHP555) supports the approval of this New Drug Application (NDA). 19 October 2018
Something like 20,000 conference delegates are gathered in Munich for the start of what promises to be another important meeting of the European Society of Medical Oncology. 19 October 2018
A new report from industry analyst the IQVIA Institute finds that, with a record-breaking number of new approvals, orphan drugs accounted for 9.6% of total sales in the USA last year. 18 October 2018
AbbVie today announced that it has entered into a research and development collaboration designed to advance a number of Morphic Therapeutic's oral integrin therapeutics for fibrosis-related indications. 18 October 2018
Swiss giant Novartis has released an upbeat financial results statement for the third quarter of 2018, with a 3% rise in revenues to $12.8 billion, roughly in line with analysts’ expectations. 18 October 2018
Swiss pharma giant Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. 18 October 2018
When the European Commission published its report on the State of Health in the European Union last year, it recognized five ongoing trends in health system reform: shifting to prevention, stronger primary care, integration of care, supporting a resilient health workforce and developing better patient-centered data. 18 October 2018
The market for targeted therapies in hepatocellular carcinoma (HCC) is still sparse and homogeneous in terms of MOAs and combinations, providing an opportunity for pharma and biotech developers to capture some of this market with diverse novel agents. 17 October 2018
Japan’s Eisai and partner Purdue Pharma today released positive top-line results from SUNRISE 2, a long-term Phase III efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. 17 October 2018
Sumitomo Dainippon Pharma has announced a 700 million yen ($6 million) investment in a company that aims to enhance the functionality of cyborg technologies and the combination of bio-signal processing and robotics. 17 October 2018
Diurnal has provided an update on its Alkindi (hydrocortisone) and Chronocort (hydrocortisone) program, stating that a further analysis of data shows a more promising result than it had first thought. 17 October 2018
Roche today released sales figures for the first nine months of 2018, showing that group sales increased 7% at constant exchange rates and in Swiss francs to 40.08 billion francs $40.48). The company does not reveal any profit figures at the quarterly stage. 17 October 2018
Among the millions of perspectives for UK Prime Minister Theresa May to consider during Wednesday’s talks with European Union (EU) leaders over a Brexit deal is that of AstraZeneca, one of the largest UK drugmakers. 17 October 2018
Daiichi Sankyo has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). 17 October 2018
In terms of revenue, the global pneumococcal vaccines market is projected to register a compound annual growth rate (CAGR) of 9.1% over the 2018-2028 forecast period. 16 October 2018
Shares in Johnson & Johnson rose 2% within an hour's trading on Tuesday after the US healthcare giant presented its third-quarter financial results, which saw the Janssen pharma unit post particularly impressive sales figures. 16 October 2018
The White House has signalled its intention to press ahead with proposals to force drugmakers to include drug pricing information in direct-to-consumer advertising, despite the apparent inability of Congress to sign up to the idea. 16 October 2018
Japanese pharma major Eisai has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratórios, which has a business foundation in Latin America. 16 October 2018
After what chief executive Stefan Oschmann said had been a “challenging year” for Germany’s Merck KGaA, the company is targeting a return to profitable growth in 2019. 16 October 2018
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.